Clinical trial
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory…
NCT00134706 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00134706 |
|---|---|
| Title | A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer |
| Official title | A Phase II Study of Docetaxel Plus Carboplatin in Hormone Refractory Prostate Cancer Patients Refractory to Prior Docetaxel-based Chemotherapy |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Bristol-Myers Squibb Industry Beth Israel Deaconess Medical Center Lowell General Hospital Massachusetts General Hospital Oregon Health and Science University Wentworth-Douglass Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Carboplatin |
| Enrollment | 30 |
| Start date | Jan 1, 2004 |
| Primary completion | Apr 1, 2006 |
| Completion | Sep 1, 2009 |
| First posted | Aug 25, 2005 |
| Last update posted | Dec 9, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: